Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer
- 30 April 2009
- journal article
- research article
- Published by Elsevier BV in КАРДИОЛОГИЯ УЗБЕКИСТАНА
- Vol. 2 (4), 291-299
- https://doi.org/10.1016/j.jcin.2008.11.015
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Angiographic Surrogate End Points in Drug-Eluting Stent Trials: A Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled TrialsJournal of the American College of Cardiology, 2008
- Drug-Eluting Stent Update 2007Circulation, 2007
- Late Restenosis Following Sirolimus-Eluting Stent ImplantationThe American Journal of Cardiology, 2007
- Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen LossCirculation, 2006
- Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting StentsCirculation, 2005
- Surrogates, substudies, and real clinical end points in trials of drug-eluting stentsJournal of the American College of Cardiology, 2005
- Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trialJournal of the American College of Cardiology, 2005
- Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting StentsCirculation, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryThe New England Journal of Medicine, 2003
- Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary ArteriesCirculation, 2002